TAKARA BIO INC. Logo

TAKARA BIO INC.

Provides life science research tools, gene therapies, and CDMO services for improving human health.

4974 | T

Overview

Corporate Details

ISIN(s):
JP3460200003
LEI:
Country:
Japan
Address:
草津市野路東七丁目4番38号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Takara Bio Inc. is a global biotechnology company dedicated to improving human health through innovative life science research tools and gene therapies. The company supplies a comprehensive portfolio of reagents, kits, instruments, and services to researchers focused on gene discovery, regulation, and function. Its offerings support a wide range of applications, including single-cell analysis, sequencing, immune profiling, and stem cell research. Additionally, Takara Bio is a key player in the development of cutting-edge medical technologies, focusing on gene and cell therapies for cancer and other diseases. The company also provides contract development and manufacturing (CDMO) services, supporting partners in the production of therapeutic products.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-12 03:15
Registration Form
確認書
Japanese 8.1 KB
2025-11-12 03:13
Interim / Quarterly Report
半期報告書-第24期(2025/04/01-2026/03/31)
Japanese 191.8 KB
2025-06-30 02:46
AGM Information
臨時報告書
Japanese 27.5 KB
2025-06-20 07:27
Registration Form
確認書
Japanese 8.1 KB
2025-06-20 07:26
Governance Information
内部統制報告書-第23期(2024/04/01-2025/03/31)
Japanese 23.6 KB
2025-06-20 07:24
Annual Report
有価証券報告書-第23期(2024/04/01-2025/03/31)
Japanese 1.7 MB
2025-05-13 09:11
Board/Management Information
臨時報告書
Japanese 21.8 KB
2024-11-11 02:37
Regulatory Filings
確認書
Japanese 8.1 KB
2024-11-11 02:36
Interim / Quarterly Report
半期報告書-第23期(2024/04/01-2025/03/31)
Japanese 167.8 KB
2024-07-01 04:07
AGM Information
訂正臨時報告書
Japanese 36.9 KB
2024-06-28 04:30
AGM Information
臨時報告書
Japanese 27.3 KB
2024-06-27 06:14
Governance Information
内部統制報告書-第22期(2023/04/01-2024/03/31)
Japanese 22.7 KB
2024-06-27 06:13
Registration Form
確認書
Japanese 8.1 KB
2024-06-27 06:12
Annual Report
有価証券報告書-第22期(2023/04/01-2024/03/31)
Japanese 1.8 MB
2024-02-14 07:42
Report Publication Announcement
確認書
Japanese 8.1 KB

Automate Your Workflow. Get a real-time feed of all TAKARA BIO INC. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for TAKARA BIO INC.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for TAKARA BIO INC. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Clinical-stage biopharma developing oral therapies for neuropsychiatric diseases like schizophrenia.
United States of America
LBRX
L&C BIO Co., Ltd Logo
Develops tissue grafts, medical devices, and cosmetics for tissue regeneration medicine.
South Korea
290650
LEAP THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing targeted immuno-oncology antibody therapies for cancer.
United States of America
LPTX
Legend Biotech Corp Logo
Develops and commercializes CAR-T cell therapies for cancer, including CARVYKTI® for myeloma.
United States of America
LEGN
LENZ Therapeutics, Inc. Logo
Develops a prescription eye drop for presbyopia, the age-related loss of near vision.
United States of America
LENZ
Lexeo Therapeutics, Inc. Logo
Develops AAV gene therapies for genetic cardiovascular and Alzheimer's diseases.
United States of America
LXEO
LEXICON PHARMACEUTICALS, INC. Logo
Develops gene-based drugs for chronic diseases, including treatments for heart failure.
United States of America
LXRX
Lidds AB Logo
Develops oncology drugs using a technology for local, controlled, and sustained drug release.
Sweden
LIDDS
LIFECORE BIOMEDICAL, INC. \DE\ Logo
A CDMO for parenteral drugs, producing injectable-grade sodium hyaluronate (HA).
United States of America
LFCR
Liminatus Pharma, Inc. Logo
Clinical-stage immuno-oncology firm developing cancer therapies targeting the CD47 checkpoint.
United States of America
LIMN

Talk to a Data Expert

Have a question? We'll get back to you promptly.